ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Multiple myeloma affects many systems in the body, including the bones, blood, kidneys, and immune system. The symptoms that may have sent you to the doctor in the first place, such as back or leg ...

Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous ...

Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. For nearly 30 years, Dr. Jim Omel has had a front row seat to the ...

Regeneron Pharmaceuticals is expanding its cancer drug lineup with FDA approval of a bispecific antibody it developed for multiple myeloma, the second most common type of blood cancer. In multiple ...